Home > Oncology > Some older women with common breast cancer can skip adjuvant chemo

Some older women with common breast cancer can skip adjuvant chemo


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
2020 San Antonio Breast Cancer Symposium
Reuters Health - 09/12/2020 - Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one to three positive lymph nodes and a low risk of recurrence can safely forego adjuvant chemotherapy, according to the first results of the RxPONDER trial. This finding is expected to save "tens of thousands of postmenopausal women the time, expense and potentially harmful side effects that can be associated with chemotherapy infusions," said Dr. Kevin Kalinsky, with the Winship Cancer Institute of Emory University, in Atlanta, during a media briefing at the virtual 2020 San Antonio Breast Cancer Symposium (SABCS). In contrast to postmenopausal women, premenopausal women with positive nodes do benefit significantly from chemotherapy, the results suggest. The RxPONDER trial follows the "landmark" TAILORx trial, which demonstrated that postmenopausal women with lymph node-negative, HR-positive, HER...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on